国科恒泰分析师会议-20250918

1. Report Industry Investment Rating There is no information provided in the content regarding the report industry investment rating. 2. Core Viewpoints of the Report - The global high - value medical consumables market is expected to reach $347.8 billion in 2031, with a compound growth rate of 8.4% from 2025 - 2031. The Chinese high - value medical consumables market is currently under pressure but has great potential in the future due to the release of demand from an aging population [23][24]. - The medical device industry has long - term growth potential driven by factors such as the "Healthy China 2030" strategy, aging population, and technological innovation. The market size of Chinese medical devices in 2024 was about 1.0638 trillion yuan, and the growth rate from 2025 - 2030 is expected to be about 3% [31][32]. - The company's innovative business model, national service network, integrated control, and digital supply chain capabilities give it significant competitive advantages in the medical device industry [38][39][40]. 3. Summary by Relevant Catalogs 3.1. Research Basic Situation - The research object is Guoke Hengtai, and the reception time is September 17, 2025. The listed company's reception personnel include the chairman, general manager, independent director, and other executives [16]. 3.2. Detailed Research Institutions - The reception objects are investors who participated in the company's 2025 semi - annual online performance briefing online, and the reception object type is "other" [19]. 3.3. Research Institution Proportion There is no information provided in the content regarding the research institution proportion. 3.4. Main Content Data 3.4.1. Market Situation of High - value Medical Consumables - The global high - value medical consumables market maintains a steady growth trend, but faces challenges such as rising raw material prices, capital market fluctuations, and supply chain disruptions. The Chinese market is under pressure from volume - based procurement but will have greater space in the future with the release of demand [23][24]. 3.4.2. Warehouse and Logistics Network - As of June 30, 2025, the company has 111 branches and subsidiaries in 31 provinces, municipalities, and autonomous regions, with a 2 - hour delivery radius covering over 80% of tertiary hospitals in China. It completed 80,000 surgical support operations in the first half of 2025. The company has 9 third - party warehouses in 8 cities, which can improve operational efficiency and reduce costs [25]. 3.4.3. Informatization System Construction - The company has a mature information system, using cloud computing and other advanced technologies to build four middle - platform support architectures. It has formed an industry - leading information management system, achieving real - time interaction of internal and external information, and promoting the digital transformation of the medical device supply chain [25][26]. 3.4.4. Market Value Management - The company attaches great importance to market value management, including strengthening top - level design, focusing on enhancing investment value, and normalizing the market value management working mechanism [34][35][36]. 3.4.5. Digital Supply Chain - The company has developed a digital core product "Juxietong", which provides comprehensive solutions for medical device manufacturers, helps with channel collaboration, and reduces costs and risks at the hospital end [29][30][31]. 3.4.6. Industry Development Trends and Policy Support - The medical device industry has long - term growth potential. In 2025, the state introduced policies to support the high - quality development of the industry, such as promoting the construction of a unified national market and optimizing the review and approval process [31][33]. 3.4.7. Tianjin Public Bonded Warehouse - In April 2025, the company's public bonded warehouse in Tianjin completed its first cargo storage. It can reduce the operating costs of medical device enterprises and shorten the turnover time of goods [34]. 3.4.8. Business Model and Competitive Advantages - The company's innovative business model of "one - stop product distribution platform + hospital - end service platform" and its national service network, integrated control, and digital supply chain capabilities form significant competitive advantages [38][39][40]. 3.4.9. Risk Control - The company has established a complete risk control system, covering the whole process from project initiation to execution, and will continue to optimize risk management [42]. 3.4.10. Cooperation with Manufacturers - The company has become a fixed partner of well - known domestic and foreign medical device manufacturers in the Chinese mainland, with product lines covering multiple departments [42]. 3.4.11. Operating Cash Flow - In the first half of 2025, the company's operating cash flow reached 387 million yuan, a year - on - year increase of 11.21% [44].